Cargando…
Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells
Due to doxorubicin (Dox) cardiotoxicity, the next generation of novel non-cardiotoxic anthracyclines, including AD 312 and AD 198, were synthesized and validated. In this study, we assessed the efficacy and mechanisms of anthracyclines-induced apoptosis and inhibition of cell viability in human blad...
Autores principales: | Pandey, Sony, Bourn, Jennifer, Cekanova, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033348/ https://www.ncbi.nlm.nih.gov/pubmed/29983877 http://dx.doi.org/10.18632/oncotarget.25530 |
Ejemplares similares
-
Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A
por: Bourn, Jennifer, et al.
Publicado: (2019) -
Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro
por: Bourn, Jennifer, et al.
Publicado: (2018) -
Detection of carcinogen-induced bladder cancer by fluorocoxib A
por: Bourn, Jennifer, et al.
Publicado: (2019) -
p53 mutations in urinary bladder cancer
por: Berggren, P, et al.
Publicado: (2001) -
Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer
por: Smolensky, Dmitriy, et al.
Publicado: (2016)